about
A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and BrazilMore efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effectsToward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg ExcretionThe Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD)Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South AsiaThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataEffect of Promotional Initiatives on Visits to a Dedicated Website for Physical Activity and Non-Communicable Disease in Luxembourg: An Event Study.A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.The epidemiology of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in community-living seniors: protocol of the MemoVie cohort study, Luxembourg.Dysautonomia in narcolepsy: evidence by questionnaire assessmentLack of polysomnographic Non-REM sleep changes in early Parkinson's disease.Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.Lifelong exposure to multilingualism: new evidence to support cognitive reserve hypothesisFixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal.Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Prevalence of Dementia and Cognitive Complaints in the Context of High Cognitive Reserve: A Population-Based StudyAdding anthropometric measures of regional adiposity to BMI improves prediction of cardiometabolic, inflammatory and adipokines profiles in youths: a cross-sectional study.Assessing drivers of full adoption of test and treat policy for malaria in Senegal.Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients.Development of a self-reporting questionnaire, BURMIG, to evaluate the burden of migraineEfficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal.Geometric least squares means ratios for the analysis of Plasmodium falciparum in vitro susceptibility to antimalarial drugs.Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western SenegalImplementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural SenegalTolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial.Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies.A daily glass of red wine and lifestyle changes do not affect arterial blood pressure and heart rate in patients with carotid arteriosclerosis after 4 and 20 weeks.Alternative visual displays of metaanalysis of malaria treatment trials to facilitate translation of research into policy.New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.Agreement Between 35 Published Frailty Scores in the General Population.Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment.Practical dosing of praziquantel for schistosomiasis in preschool-aged children.Subtraction of subcutaneous fat to improve the prediction of visceral adiposity: exploring a new anthropometric track in overweight and obese youth.Reverse remodelling through exercise training is more pronounced in non-ischemic heart failure.Relationship between entomological inoculation rate, Plasmodium falciparum prevalence rate, and incidence of malaria attack in rural Gabon.Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon.Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine.Myocardial MIBG scintigraphy: a useful clinical tool? : A retrospective study in 50 parkinsonian patients.
P50
Q28478552-FB86A706-929C-4929-8132-932286C30ABCQ28483969-6977B3BC-8C4F-4471-8A1A-25568C06CC08Q28548465-8801617D-83EF-44B2-A82B-6188B78995B8Q28552173-47FD5032-4A86-4768-AE4B-6EF272196417Q28741732-26DA9633-6C11-40DE-A6CD-AB36A1902FD1Q30936416-192CAFB7-4CFB-4F53-8BE2-D2AC27393B80Q33734703-345DD026-0E73-40AE-85B5-4D0E480909DAQ33906157-BDEFD68C-6905-4190-9953-0962A99A13EEQ34334180-BCF57BD7-A1F5-4B12-9563-856C9FECD1A3Q34346556-5447502E-3E7B-4432-A00C-18A9C8D8B563Q34548263-E2982A52-8BBF-4C67-B353-2DC28E5C29E4Q34654206-B46A4C6C-8ED7-494A-A2E4-6AF40C8DB96EQ34706695-9C85D727-2845-4C8B-829A-DB4263524155Q34996451-67894279-69FE-4B1A-95EF-7F145D00A990Q35177727-ED4D9BFB-7AB4-4E7F-9108-3CF108678580Q35245962-6C9C4B26-3DA3-4C48-A5D5-830E68A8765CQ35782001-B7097096-136C-4F7F-A5AA-15365BE1A64CQ35819585-68A164E2-3158-44B9-B260-3F5E96286985Q35836617-1FFC59C6-EB4A-4210-A53F-FA6BA1C00045Q36157532-801F4951-9B8E-456E-A1A8-4926A80F2670Q36260925-BC81C1D2-D4BF-4284-86F6-F0B9125E403FQ36398987-75AFEAE6-28BE-428E-8C06-E4E7216F1F82Q36449476-2032A692-EC8D-49AC-891E-0324DCA0B31EQ36544502-66FBD919-9CB0-4268-8EE3-27A74FFEABBAQ36987050-129D2004-A502-4178-B388-47225070FCCCQ37272811-EE722F7F-1D1B-40C6-BA0D-9F4A7E45C657Q37324802-C1AA7E51-4E47-4AAD-8CBE-8BA8DD40B58BQ37351463-72AC18A8-7F7E-43E7-9EFE-DAEF6B5EDAA6Q37446962-03B4EB4A-0FE1-403F-8B31-CF336EF184F8Q37811337-18D7EC5F-8019-4C79-A39E-A3335D845B35Q38387210-248C2CD1-49C1-42BB-86AF-3D02732053ABQ38716914-61BC4407-5592-4B2F-9A6B-07BAB24947C8Q39322820-D554AB77-1C6F-4DAC-B95E-B5CFFBF2A2A3Q39322915-76952D77-27C1-43D5-A8D5-E2AA9A7E8886Q39613785-4504B964-6586-4698-8972-058DD83925BCQ40060399-F614BD1E-A959-4B0E-AFFC-9BD191F69865Q40562692-A9E937FC-EB2F-47E0-960A-B39343BB5262Q41927758-21A84608-9141-4C74-A709-E03BCA33E0DAQ41945631-4E0C6E12-E469-4C05-9157-0A8082BB7F9BQ43162305-5A458C71-70AF-41E2-BC6E-FFAE8B12EF6E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michel T Vaillant
@ast
Michel T Vaillant
@en
Michel T Vaillant
@es
Michel T Vaillant
@nl
type
label
Michel T Vaillant
@ast
Michel T Vaillant
@en
Michel T Vaillant
@es
Michel T Vaillant
@nl
altLabel
michel vaillant
@en
prefLabel
Michel T Vaillant
@ast
Michel T Vaillant
@en
Michel T Vaillant
@es
Michel T Vaillant
@nl
P106
P1153
23475593900
P21
P2798
P31
P496
0000-0003-4714-8128